Latest News for: cml
Edit
Prospectus by Investment Company (Form 497) (Cml Variable Annuity Account A)
Public Technologies 27 Apr 2026
). Supplement dated April 27, 2026 ... Account A. Account B. Issued by Massachusetts Mutual Life Insurance Company ... Cml Variable Annuity Account A published this content on April 27, 2026, and is solely responsible for the information contained herein.
Edit
Prospectus by Investment Company (Form 497) (Cml Variable Annuity Account B)
Public Technologies 27 Apr 2026
). Supplement dated April 27, 2026 ... Account A. Account B. Issued by Massachusetts Mutual Life Insurance Company ... Cml Variable Annuity Account B published this content on April 27, 2026, and is solely responsible for the information contained herein.
Edit
NCCN Announces Awards for Improvement Initiatives for Chronic Myeloid Leukemia (CML)
PR Newswire 23 Apr 2026
The National Comprehensive Cancer Network announces funding for selected quality improvement research projects to utilize digital tools for improving decision-making and quality of life for people with CML.
Edit
Annual Notice of Securities Sold (Form 24F-2NT) (Cml Variable Annuity Account B)
Public Technologies 27 Mar 2026
Edit
Annual Notice of Securities Sold (Form 24F-2NT) (Cml Accumulation Annuity Account E)
Public Technologies 27 Mar 2026
Edit
Annual Notice of Securities Sold (Form 24F-2NT) (Cml Variable Annuity Account A)
Public Technologies 27 Mar 2026
Edit
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Pharmiweb 25 Mar 2026
Edit
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML (Form 8-K) (Terns Pharmaceuticals Inc)
Public Technologies 25 Mar 2026
kinase inhibitor currently in Phase 1/2 development for certain patients with CML ... Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of CML ... with CML.
Edit
Financial Statements by Insurance Company (Form N-VPFS) (Cml Variable Annuity Account A)
Public Technologies 20 Mar 2026
Edit
Financial Statements by Insurance Company (Form N-VPFS) (Cml Accumulation Annuity Account E)
Public Technologies 20 Mar 2026
Edit
Financial Statements by Insurance Company (Form N-VPFS) (Cml Variable Annuity Account B)
Public Technologies 20 Mar 2026
Edit
Annual Report by Investment Company (Form N-CEN) (Cml Variable Annuity Account A)
Public Technologies 13 Mar 2026
Edit
Annual Report by Investment Company (Form N-CEN) (Cml Variable Annuity Account B)
Public Technologies 13 Mar 2026
Edit
Annual Report by Investment Company (Form N-CEN) (Cml Accumulation Annuity Account E)
Public Technologies 13 Mar 2026
Edit
Certara Simcyp� Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Nasdaq Globe Newswire 03 Mar 2026
Certara's Simcyp Simulator enabled modeling predictions accepted by the FDA in lieu of clinical studies to support the approval of asciminib ... .
- 1
- 2
- Next page »